Patterns of Failure after Stereotactic Body Radiation Therapy or Lobar Resection for Clinical Stage I Non-Small-Cell Lung Cancer: Erratum  by unknown
1343Journal of Thoracic Oncology  •  Volume 8, Number 10, October 2013
Erratum
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American 
Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology: Erratum
A recently published article [Lindeman NI, Cagle PT, Beasley MB, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR 
and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, 
and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859] contains an error in Table 4, EGFR Mutation Prevalence in Different Lung 
Adenocarcinoma Patient Populations, and in Supplemental Table 5, EGFR Mutation Prevalence in Different Lung Adenocarcinoma Patient Populations. 
These analyses failed to distinguish between European Spanish and Latin American (Hispanic) populations. Re-analysis of the 4 studies originally cited 
as providing data for Latin American (Hispanic) populations led to the re-categorization of 369 patients, with only 3 remaining Latin American (Hispanic) 
patients, which was too limited for meaningful analysis of this population. The re-categorization of the remaining 369 patients did not make a significant 
change in the data for the other patient populations as originally presented in Table 4 and in Supplemental Table 5.
Reference:
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. 
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American 
Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859.
Erratum
Asbcopal Effects after Conventional and Stereotactic Lung Irradiation of Non-Small-Cell Lung Cancer: Erratum
The title of this article contained a spelling error and should have appeared as follows:
Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non-Small-Cell Lung Cancer
Reference:
Siva S, Callahan J, MacManus MP, Martin O, Hicks RJ, Ball DL. Asbcopal Effects after conventional and stereotactic lung irradiation of non-small-cell lung 
cancer. J Thorac Oncol. 2013;8:e71–e72.
Erratum
Patterns of Failure after Stereotactic Body Radiation Therapy or Lobar Resection for Clinical Stage I Non-Small-Cell Lung Cancer: Erratum
The article that appeared on page 192 of the February 2013 issue of the Journal of Thoracic Oncology contained an error. The first sentence of the article 
should have appeared as follows:
For patients with medically operable clinical stage I non–small-cell lung cancer (NSCLC), lobectomy or pneumonectomy results in primary tumor control 
approaching 100% and 5-year overall survival of 53% and 43% for tumors 2 cm or less and 2.1 to 5 cm, respectively.1,2
Reference:
Robinson CG, DeWees TA, El Naqa IM, Creach KM, Olsen JR, Crabtree TD, Meyers BF, Puri V, Bell JM, Parikh PJ, Bradley JD. Patterns of failure after 
stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol. 2013;8:192–201.
